CD33

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

Retrieved on: 
Thursday, January 4, 2024

Appointed internationally recognized immuno-oncology expert Dr. Corinne Epperly, M.D., M.P.H., to IN8bio’s Board of Directors

Key Points: 
  • Appointed internationally recognized immuno-oncology expert Dr. Corinne Epperly, M.D., M.P.H., to IN8bio’s Board of Directors
    NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today highlighted recent business updates and provided pipeline goals for 2024.
  • “2023 was a year marked by strong execution for IN8bio.
  • Importantly, we are excited that we are seeing in vivo expansion and persistence of allogeneic gamma-delta T cells, now out to 365 days.
  • INB-300: Present additional preclinical data demonstrating proof-of-concept for the nsCAR platform targeting CD33 and CD123 at American Association for Cancer Research (AACR) 2024.

Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

Retrieved on: 
Friday, December 22, 2023

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for SENTI-202, an off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies while sparing healthy bone marrow cells.

Key Points: 
  • The dose finding trial will evaluate two dose levels, either 1 or 1.5 billion SENTI-202 cells, administered after lymphodepleting conditioning in adult patients with relapsed or refractory (r/r) CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia (AML).
  • “Clearance of our IND application for SENTI-202 is a tremendous milestone and marks an important achievement for Senti as we transition to a clinical-stage therapeutics company,” said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio.
  • Senti Bio believes this approach can lead to more effective and durable responses in patients.
  • Through Senti Bio’s previously announced agreement with GeneFab, the Company has prepaid the majority of manufacturing-related expenses through the completion of the Phase 1 trial.

Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)

Retrieved on: 
Tuesday, November 14, 2023

The presentation will focus on the multiple ways Molecular Partners has designed DARPins to activate the immune system against cancer only under certain conditions.

Key Points: 
  • The presentation will focus on the multiple ways Molecular Partners has designed DARPins to activate the immune system against cancer only under certain conditions.
  • This conditional activation is intended to focus immune attack more specifically against tumor cells and minimize damage to healthy cells, a major challenge for current oncology drugs and development efforts.
  • The SWITCH-DARPin platform, a versatile novel DARPin design for conditionally triggering an immune cell attack only in the presence of defined tumor antigens.
  • The portfolio of RDT candidates represent a unique delivery system for radioactive payloads to solid tumors and has significantly expanded the company’s work in oncology therapeutics.

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Retrieved on: 
Thursday, November 9, 2023

Additionally, platelet recovery occurred at a median of 15.5 days, excluding one patient with previously documented anti-platelet antibodies (immune thrombocytopenia).

Key Points: 
  • Additionally, platelet recovery occurred at a median of 15.5 days, excluding one patient with previously documented anti-platelet antibodies (immune thrombocytopenia).
  • This data further validates Vor Bio’s approach of using transplant donor cells as CAR-T starting material that are healthy, stem-like, and exactly matched to the patient’s immune system.
  • Vor Bio management will host a live webcast today at 4:30 PM ET.
  • A replay of the webcast will be available via the investor section of the Company’s website at www.vorbio.com approximately two hours after the call’s conclusion.

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023

Updated Phase 1 clinical data from INB-200 to be presented at Society for Neuro-Oncology (SNO) on November 17, 2023.

Key Points: 
  • Updated Phase 1 clinical data from INB-200 to be presented at Society for Neuro-Oncology (SNO) on November 17, 2023.
  • NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced financial results, operational highlights and recent corporate developments for the third quarter ended September 30, 2023.
  • The presentation at ASH will highlight clinical data updating the efficacy results of INB-100 including complete responses (CRs) and durability.
  • Cash: As of September 30, 2023, the Company had cash of $12.9 million, compared to $17.0 million as of June 30, 2023.

Cimeio Therapeutics Presents Data for its CD45 Universal Heme ADC at ASH

Retrieved on: 
Tuesday, December 12, 2023

Cimeio Therapeutics, the leading biotechnology company in the field of epitope shielding, presented data for its CD45 and CD33 programs during this weekend’s American Society of Hematology (ASH) meeting in San Diego.

Key Points: 
  • Cimeio Therapeutics, the leading biotechnology company in the field of epitope shielding, presented data for its CD45 and CD33 programs during this weekend’s American Society of Hematology (ASH) meeting in San Diego.
  • The two studies provide further evidence that epitope editing allows for the development of powerful immunotherapies that would not be safe to administer without first protecting healthy cells.
  • After just two doses of CIM053-ADC, all mice were cancer-free while the healthy hematopoietic cells were unaffected.
  • This study demonstrates the potential of CD45-targeted ADC therapy for patients with hematologic malignancies.

Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition

Retrieved on: 
Friday, December 8, 2023

Sandesh Seth, Actinium's Chairman & CEO, said, "We are particularly excited for this year's ASH as our four presentations will highlight the differentiated capabilities of Iomab-B and Actimab-A.

Key Points: 
  • Sandesh Seth, Actinium's Chairman & CEO, said, "We are particularly excited for this year's ASH as our four presentations will highlight the differentiated capabilities of Iomab-B and Actimab-A.
  • Better treatment options and outcomes are needed in AML, particularly for elderly patients and those with relapsed or refractory disease who represent a majority of the population.
  • Our strong presence at ASH is indicative of the potential that our targeted radiotherapies have in the management of patients with difficult to treat AML.
  • Details of Actinium's presentations at ASH are as follows:
    Room: Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19
    Session Name: 616.

Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, November 7, 2023

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2023, and provided a business update.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2023, and provided a business update.
  • Research & Development (R&D) Expenses: R&D expenses for the third quarter of 2023 were $27.6 million, compared to $16.9 million for the third quarter of 2022.
  • General & Administrative (G&A) Expenses: G&A expenses for the third quarter of 2023 were $7.7 million, compared to $7.2 million for the third quarter of 2022.
  • Net Loss: Net loss for the third quarter of 2023 was $33.2 million, compared to $23.8 million for the third quarter of 2022.

Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platform

Retrieved on: 
Thursday, November 2, 2023

An abstract providing a clinical update from the VBP101 clinical trial (NCT048499910), a Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (VOR33) in patients with AML, was accepted by ASH for oral presentation.

Key Points: 
  • An abstract providing a clinical update from the VBP101 clinical trial (NCT048499910), a Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (VOR33) in patients with AML, was accepted by ASH for oral presentation.
  • This data supports robust neutrophil engraftment of trem-cel and provides evidence of hematologic protection from MylotargTM, a CD33-targeted antibody drug conjugate.
  • An updated data release from VBP101 is expected by the Relapse After Transplant and Cellular Therapy (HSCT²) conference taking place November 10-11, 2023.
  • Dr. Tasian commented: “The interim results from our CD33 CAR T cell immunotherapy clinical trial are very encouraging.

Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition

Retrieved on: 
Thursday, November 2, 2023

MP0533 is in development for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndrome (AML/MDS).

Key Points: 
  • MP0533 is in development for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndrome (AML/MDS).
  • As of data cut-off (20 July 2023) of the abstract published today, five patients across three dosing regimens had been treated.
  • The Company anticipates to present data including from the fourth dose cohort at the ASH Annual Meeting and Exposition in December this year.
  • “The data from the ASH abstract represent the beginning of an exciting and encouraging clinical journey for the MP0533 program.